Leafy Tunnel

VC London, United Kingdom · Founded 2020

Website

Leafy Tunnel is an early-stage venture capital firm investing in alternative medicine, specifically focusing on medical cannabis and psychedelics to address mental health and pain disorders.

About Leafy Tunnel

Leafy Tunnel is a UK-based early-stage venture fund focused on backing companies that develop alternative therapeutics for mental health and chronic conditions, with a particular emphasis on psychedelic therapeutics, novel mental health interventions, and selectively related digital health platforms. The fund writes initial checks of roughly GBP 250K to GBP 1.5M at seed and pre-seed, typically as a co-investor with selective small lead capacity. Healthcare exposure is total and concentrated in mental health, psychedelic therapeutics, and chronic disease alternatives. AI focus is welcome where it sits inside a defensible therapeutics or digital therapeutic product. Founders best suited are seed-stage CEOs in psychedelic therapeutics, mental health digital therapeutics, or alternative chronic disease interventions with strong scientific or clinical credentials and a clear regulatory path, who want a thesis-aligned investor with deep relationships in the psychedelic and mental health ecosystem. Founders who do not fit include traditional digital health software without a therapeutics angle, devices, capital-intensive biotech requiring large rounds, and consumer wellness without clinical evidence. Geographic preference is UK and Europe with selective exposure to US and Canadian psychedelic therapeutics. The entry path is warm introduction through a portfolio CEO, a psychedelic therapeutics operator, or a co-investor at funds like Atai Life Sciences-affiliated investors or Conscious Fund. LinkedIn outreach to a partner with a focused therapeutics thesis and clinical or scientific traction summary is a reasonable secondary option. Expect deep scientific and regulatory diligence specific to psychedelic therapeutics and a partner that values clinical evidence and regulatory navigation.